Alex Zhavoronkov is a Latvian-born scientist and entrepreneur known for his work in artificial intelligence applied to drug discovery, aging research, and regenerative medicine. As of 2024, he is the founder and CEO of Insilico Medicine, a company that uses Generative AI to design novel therapeutics, and the director of the Biogerontology Research Foundation, a UK-based think tank focused on aging research. He has authored or co-authored over 250 scientific articles and several books, including The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy (2013).
Zhavoronkov's career has spanned computer graphics, biotechnology, and artificial intelligence, and he has become a prominent voice in the longevity community, often advocating for the integration of AI in the creation of treatments for age-related diseases. His controversial statements and projects, including a viral video about head transplants and the co-authorship of a paper that formally credited ChatGPT, have drawn both attention and criticism.
Early Life and Education
Zhavoronkov, born Aleksandrs Zavoronkovs in Latvia, showed an early interests in science. He received two bachelor's degrees from Queen's University before moving into the field of graphic processors, working in an industry that would later prove foundational to his AI research. He earned a master's degree in biotechnology at Johns Hopkins University and a PhD in physics and mathematics from Moscow State University.
During the 2010s, Zhavoronkov served as an adjunct professor at the Moscow Institute of Physics and Technology and became affiliated with several other institutions. As of 2024, he was an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
In May 2013, Zhavoronkov was listed as one of the co-inventors on a U.S patent for "systems and methods for communicating with a computer using brain activity patterns," reflecting his early interest in the intersection of Neural network and human cognition.
AI and Drug Discovery
In 2014, Zhavoronkov began focusing on using large data sets and artificial intelligence to accelerate the drug discovery process. He founded Insilico Medicine while at Johns Hopkins University in Baltimore, where he and colleagues began applying Generative AI to pharmacology. Early investors include Tony Robbins and Peter Diamandis, who backed the idea with enthusiasm. Robbins of noted that while researchers had been using and combining generative adversarial networks to design objects or generate fake human faces, Zhavoronkov wanted to apply them to the design of new drugs.
The company's foundational approach involved using deep learning, a subfield of Machine learning, Artificial intelligence to identify potential drug candidates and generate novel molecular structures. In November 2017, Zhavoronkov proposed applying deep learning and blockchain technology to manage human life data, to potentially increase the transparency of clinical data and accelerate research.
Through the years, Insilico engaged in several high-profile milestones. In 2019 a peer-reviewed paper in -9 Nature Biotechnology reported that in a study using of a follow-up of the paper Zhavoronkov's team to designed a deep learning of DDR1 kinase inhibitors, demonstrating the power for AI-designed compounds reaches in a matter of weeks.
In 2022, Zhavoronkov raised the $60 million in round of financing for Insilico. At the time, he pointed out that the industry was in a "biotechnology winter" in which many companies were running out of cash and were dying. He posited that his fundraising, built on two major deals with large corporations, was positioning Insilico Medicine for a coming "biotech spring." AI writer Calum Chace commented that Zhavoronkov was known within the longevity community for his relentless focus, in a profile.
Generative AI Drug
A major milestone came in June 2023, when Zhavoronkov announced that Insilico Medicine had developed what he described as "the first fully generative AI drug to reach human clinical trials, and specifically Phase II trials with patients." Could this claimed to be the first time a drug candidate created by a generative adversarial network had entered into clinical tests with patients.
In 2024, Zhavoronkov moved the company's headquarters from Baltimore to Boston, Massachusetts, likely to be in the heart of the U.S. biotech center, to leverage the regional's talent and capital.
Controversies and Ethical Debates
Zhavoronkov's work has often raised ethical issues around the field of AI and biotechnology, including and. In February 2023, a National Review column by Wesley J. Smith sharply criticized a Zhavoronkov comment on organ transplants. Zhavoronkov had observed that in order to facilitate human life extension, organ transplants could someday be provided by using clones of humans that would be generated without cognitive functions. Smith contended that this idea was a moral hazard and posed a a slippery slope to dehumanizing practices.
In May 2024, Zhavoronkov funded the production of 3D-printed, realistically animated heads of his own doppelgänger, a medical illustration of a human head, and a visually realistic rendering of a head transplant. In the video, which became viral on social media, the head transplant subject was displayed with Zhavoronkov's own face. The video generated media coverage and discussion on the ethical implications of such visual simulations.
Additionally, in 2022, Zhavoronkov was an author on a paper titled "Rapamycin in the context of Pascal's Wager: generative pre-trained transformer perspective," which was described as one of the first peer-reviewed papers to explicitly credit a large language model, ChatGPT, as a coauthor. Zhavoronkov reported that when he asked ChatGPT itself whether it should be named as a coauthor, it responded "with multiple compelling reasons" why it should not. This instance of AI in academic publishing sparked wide debate.
Beyond Pharmaceuticals: AI and Internet Activities
Beyond drug discovery, Zhavoronkov has made dabbled in AI and internet-related applications. In 2016, he served as the chief science officer for Beauty.AI, an AI that evaluates people's external appearance using computerized vision algorithms. During his time, concerns arose over ethnic and color bias in the platform's assessment. Zhavoronkov insists attributed these concerns to a lack of data from those ethnic groups, rather than inherent bias in the algorithms, stating the platform needed to be trained on more global.
His work in this area also involved the application of AI to longevity and personalized health care. For instance, he encouraged the use of AI to analyze data from genomic and other large databases.
Publications and Books
Zhavoronkov's written work spans both academic literature and books for popular audiences. Since 2010, he has authored or co-authored more than 250 scientific articles indexed in PubMed, covering topics in deep learning, drug discovery, and aging.
Among his books:
- (2012) "Dating A.I.: A guide to, falling in love with Artificial Intelligence," published by RE/Search, a publisher associated with journalist Californian, New Wave culture, and the internet.
- (2013) The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy, published by Macmillan.
- (2023) Artificial Intelligence for Healthy Longevity, coauthored with Alexey Moskalev and Ilia Stambler.
These works explore how artificial intelligence, a central theme of his research, can be applied to radical longevity extension and how such advances could transform the global economy.
Insilico Medicine and the Future
Zhavoronkov's long-term vision is to use AI for drug and companion platform for drug design, so called "bio-age" detection and the interpretation of massive data sets. He under iteration to seek seed and expansion stage investments from various sources, including from venture capital and corporations, in order to maintain and grow his company. He has lived and worked in the U.S., Asia, and Europe, and his company try to build partnerships with a wide. As of 2024, the company has operations in Boston, creating the new headquarters and, in 2023, completed a Phase II trial for an AI-discovered drug.
Economic Aging and Biogerontology
Zhavoronkov is a vocal proponent for the economic implications of age-related disease. Through his role at the Biogerontology Research Foundation, he has sought to draw attention to the global economic burden of an aging population and to the potential for biotech to slow or reverse aging. He has written and spoken about the economics of an "ageless" society, including macro-level assessments of how extended health-span could reduce retirement costs and increase productivity.
Legacy and Impact
Zhavoronkov's work sits at the intersection of Machine learning, Deep learning, and medicine. He has helped establish it as a viable tool for speeding up drug design and has continued to push boundaries, both in the design of novel drug candidates, in the ethics of AI, and with the social implication of human enhancement. While he has received requests for criticism from some quarters, his work has inspired a new generation of scientists to apply AI to biomedical and the human body. His and his company's work, up to the year 2024, remains focused on to translate his vision of using AI to address the complexities of age and creating a world where everyone will live to a very old age.